Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac756 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Daniele Cappellani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Amiodarone, Hyperthyroidism, Thyrotoxicosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Context
Patients with amiodarone-induced thyrotoxicosis (AIT) often receive initial therapy for thyrotoxicosis in several different medical settings before admission to a referral center.
Objective
This work aimed to determine whether first-line medical therapy (ie, therapies for thyrotoxicosis at first diagnosis of AIT) affects the outcome of AIT patients.
Methods
A single-center historical-prospective cohort study was conducted on 313 AIT patients. Clinical and biochemical data were collected at first diagnosis, at a referral center, and during the course of AIT. Primary outcomes were cardiovascular (CV) events and hospitalizations. First-line therapies were considered appropriate when they included glucocorticoids for type 2 AIT and methimazole for type 1 AIT at the approved dose, either alone (optimal medical therapy, OMT) or in combination (right-dose combination therapy, RCT). Other therapies were considered not appropriate, including no therapy. Duration of exposure to thyrotoxicosis was the time from first diagnosis of AIT to its remission.
Results
A total of 34.5% patients received appropriate therapies (28.1% OMT, 6.4% RCT), whereas the remaining (65.5%) received inappropriate therapies. CV events and hospitalizations were more frequent in patients who received inappropriate therapies (33.2% vs 4.5%, and 24.9% vs 6.5%, respectively; P < .0001 for both). Appropriate therapies reduced serum thyroid hormone concentrations (P = .018) from first diagnosis to referral, unlike the inappropriate therapies. The duration of exposure to thyrotoxicosis was longer in patients receiving inappropriate therapies and was a risk factor for arrhythmias (hazard ratio [HR] 1.004; P = .0008), major acute CV events (HR 1.004; P = .020), and hospitalizations (HR 1.006; P < .0001).
Conclusion
The first medical therapy of AIT influences the exposure time to thyrotoxicosis and the occurrence of CV events and hospitalizations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy.
- Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
ORCID-Profile: Daniele Cappellani, Luigi Bartalena, Fausto Bogazzi
Zitieren
APA
Cappellani, D., Marconcini, G., Manetti, L., Bartalena, L., & Bogazzi, F. (2023). Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac756
Vancouver
Cappellani D, Marconcini G, Manetti L, Bartalena L, Bogazzi F. Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac756
BibTeX
@article{Cappellani2023,
author = {Cappellani, Daniele and Marconcini, Giulia and Manetti, Luca and Bartalena, Luigi and Bogazzi, Fausto},
title = {Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac756}
}
EUVIMED